EDITORIAL · RESEARCH OF RECORD
About TB-500 Source
What this project is, what "source" means here, and the line we hold between summarizing research and supplying anything.
What TB-500 Source is
TB-500 Source is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 — the Ac-LKKTETQ fragment of thymosin beta-4 — and its parent protein. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is built around a single discipline: reconciling what the literature actually establishes. Most efficacy findings attributed to "TB-500" were generated with the full-length protein, not the 7-mer, so we tag each finding by what was tested and keep the structural results, the full-length-protein results and the human-data gaps in separate columns. Every quantitative claim is cited to a study or an FDA listing, and the most common TB-500 questions answered on this site are indexed in one place.
What "source" means on this site
The word "source" in the domain name is editorial framing, not a commercial one. It is the position this publisher occupies relative to the literature — a research-of-record register that aims to be a reliable source of the facts about TB-500, the place where each figure is traced back to where it was first reported. It is not a sourcing service, a marketplace, or a supplier. We do not list prices, stock, or vendors, and nothing here is for sale.
That distinction matters for a compound surrounded by marketing. A great deal of "TB-500" promotion leans on full-length thymosin beta-4 data while selling a fragment. Our job is to draw that line in plain sight, not to obscure it.
How we handle evidence and its limits
We lead with what is established and we flag what is not. The 1:1 actin-sequestration structure is established by crystallography [1]. The wound, cardiac and neurological findings are real but were measured on the full-length protein in animals [7][6][8]. There are no completed controlled human trials of the fragment [10]. We state all three plainly, because an honest gap belongs on the record next to a finding.
We do not provide dosing, administration instructions, or guidance on obtaining the compound. We describe what was administered to which species at which dose by which route, and we report regulatory standing — including the FDA 503A category and WADA-prohibited status — from primary sources. This is general information, not medical or legal advice.